thousands chemical starting points antimalarial lead identification
malaria devastating infection caused protozoa genus plasmodium drug resistance widespread new chemical class antimalarials introduced clinical practice since recent rise parasite strains reduced sensitivity newest drugs screened nearly million compounds glaxosmithklines chemical library inhibitors p falciparum confirmed inhibit parasite growth least % mu m concentration also showed potent activity multidrug resistant strain dd2 % compounds originate internal company projects new malaria community analyses using historic assay data suggest several novel mechanisms antimalarial action inhibition protein kinases host-pathogen interaction related targets chemical structures associated data hereby made public encourage additional drug lead identification efforts research disease
